Trial Profile

A registrational trial of STRO-002 for patients with advanced ovarian cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luveltamab tazevibulin (Primary)
Indications Ovarian cancer
Focus Registrational; Therapeutic Use
Sponsors Sutro Biopharma

Most Recent Events

08 Nov 2022 According to a Sutro Biopharma media release, trial design will be presented by end of 2022.
13 May 2022 New trial record
09 May 2022 According to a Sutro Biopharma media release, Regulatory discussions for potential registrational trial planned planned for mid-year 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com